Keyphrases
Gefitinib
100%
Etoposide
100%
Novel Combination Therapy
100%
Hormone-sensitive Prostate Cancer
100%
PC-3 Cells
75%
Estrogen Receptor β
75%
Epidermal Growth Factor Receptor
50%
LNCaP
50%
DU145
50%
Ceramide
50%
Cytotoxic Effect
50%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
50%
Quantitative PCR
25%
Effective Treatment
25%
Antiproliferative Activity
25%
Nonmalignant
25%
Prostate Cancer Cells
25%
17-estradiol
25%
Expression Level
25%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
25%
Western Blot
25%
High-level Expression
25%
Topoisomerase Inhibitors
25%
Prostate Cancer Patients
25%
Androgen-independent
25%
LNCaP Cells
25%
Androgens
25%
Promising Strategies
25%
Apoptotic Cell Death
25%
Prostate Cancer Cell Lines
25%
Normal Prostate
25%
Prostate Gland
25%
Prostate Cells
25%
Prostatic Adenocarcinoma
25%
Caspase Activity
25%
FACS Analysis
25%
Epidermal Growth Factor Receptor Expression
25%
Gleason Score
25%
Mitochondrial Pathway
25%
Caspase Cascade
25%
MTT Analysis
25%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Tamoxifen
100%
Gefitinib
100%
Etoposide
100%
Combination Therapy
100%
Androgen
100%
Epidermal Growth Factor Receptor
60%
Estrogen Receptor Beta
60%
Ceramide
40%
Caspase
40%
Western Blot
20%
Antiinfective Agent
20%
Diethylstilbestrol
20%
Epidermal Growth Factor Receptor Kinase Inhibitor
20%
Beta Adrenergic Receptor Blocking Agent
20%
Prostate Adenocarcinoma
20%
Fluorescence Activated Cell Sorting
20%
Gleason Score
20%
Gyrase Inhibitor
20%